Retinoic acid attenuates rheumatoid inflammation in mice

Journal of Immunology

Volumn 189, Issue 2, 2012, Pages 1062-1071

  Kwok, Seung Ki ^a   Park, Mi Kyung ^b   Cho, Mi La ^b   Oh, Hye Jwa ^b   Park, Eun Mi ^b   Lee, Dong Gun ^b   Lee, Jennifer ^a   Kim, Ho Youn ^a,b   Park, Sung Hwan ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; LIPOPOLYSACCHARIDE; RETINOIC ACID; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CD4+ T LYMPHOCYTE; DOWN REGULATION; FIBROBLAST; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SPLEEN; SPLEEN CELL; SYNOVIOCYTE; TH17 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; CATTLE; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; IMMUNITY, HUMORAL; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED DBA; OSTEOCLASTS; TH17 CELLS; TRETINOIN;

EID: 84863624923     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102706     Document Type: Article

References (53)

1. Firestein, G. S. 1996. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum. 39: 1781-1790. (Pubitemid 26378569)
2. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Rheumatoid arthritis. Cell 85: 307-310. (Pubitemid 26160702)
3. Lipsky, P. E., D. M. van der Heijde, E. W. St Clair, D. E. Furst, F. C. Breedveld, J. R. Kalden, J. S. Smolen, M. Weisman, P. Emery, M. Feldmann, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343: 1594-1602. (Pubitemid 32162982)
4. Klareskog, L., D. van der Heijde, J. P. de Jager, A. Gough, J. Kalden, M. Malaise, E. Martín Mola, K. Pavelka, J. Sany, L. Settas, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-681. (Pubitemid 38296553)
5. Breedveld, F. C., M. H. Weisman, A. F. Kavanaugh, S. B. Cohen, K. Pavelka, R. van Vollenhoven, J. Sharp, J. L. Perez, and G. T. Spencer-Green. 2006. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54: 26-37. (Pubitemid 43122183)
6. Singh, J. A., S. Beg, and M. A. Lopez-Olivo. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst. Rev. CD008331.
7. Mark, M., N. B. Ghyselinck, and P. Chambon. 2004. Retinoic acid signalling in the development of branchial arches. Curr. Opin. Genet. Dev. 14: 591-598. (Pubitemid 39360308)
8. Pino-Lagos, K., M. J. Benson, and R. J. Noelle. 2008. Retinoic acid in the immune system. Ann. N. Y. Acad. Sci. 1143: 170-187.
9. Huang, M. E., Y. C. Ye, S. R. Chen, J. R. Chai, J. X. Lu, L. Zhoa, L. J. Gu, and Z. Y. Wang. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572.
10. Peck, G. L., T. G. Olsen, F. W. Yoder, J. S. Strauss, D. T. Downing, M. Pandya, D. Butkus, and J. Arnaud-Battandier. 1979. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N. Engl. J. Med. 300: 329-333. (Pubitemid 9114884)
11. Ward, A., R. N. Brogden, R. C. Heel, T. M. Speight, and G. S. Avery. 1983. Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs 26: 9-43. (Pubitemid 13067401)
12. Mucida, D., Y. Park, G. Kim, O. Turovskaya, I. Scott, M. Kronenberg, and H. Cheroutre. 2007. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317: 256-260. (Pubitemid 47076203)
13. Mucida, D., K. Pino-Lagos, G. Kim, E. Nowak, M. J. Benson, M. Kronenberg, R. J. Noelle, and H. Cheroutre. 2009. Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity 30: 471-472, author reply 472-473.
14. Racke, M. K., D. Burnett, S. H. Pak, P. S. Albert, B. Cannella, C. S. Raine, D. E. McFarlin, and D. E. Scott. 1995. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J. Immunol. 154: 450-458.
15. Pérez de Lema, G., F. J. Lucio-Cazaña, A. Molina, B. Luckow, H. Schmid, C. de Wit, V. Moreno-Manzano, B. Banas, F. Mampaso, and D. Schlöndorff. 2004. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int. 66: 1018-1028. (Pubitemid 39121006)
16. Kinoshita, K., B. S. Yoo, Y. Nozaki, M. Sugiyama, S. Ikoma, M. Ohno, M. Funauchi, and A. Kanamaru. 2003. Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J. Immunol. 170: 5793-5798. (Pubitemid 36617874)
17. Brinckerhoff, C. E., J. W. Coffey, and A. C. Sullivan. 1983. Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13-cisretinoic acid. Science 221: 756-758. (Pubitemid 13030631)
18. Kuwabara, K., K. Shudo, and Y. Hori. 1996. Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. FEBS Lett. 378: 153-156. (Pubitemid 26015564)
19. Beehler, B. C., Y. J. Hei, S. Chen, J. A. Lupisella, J. Ostrowski, J. E. Starrett, D. Tortolani, K. M. Tramposch, and P. R. Reczek. 2003. Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J. Rheumatol. 30: 355-363. (Pubitemid 36152605)
20. Nozaki, Y., T. Yamagata, M. Sugiyama, S. Ikoma, K. Kinoshita, and M. Funauchi. 2006. Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis. Clin. Immunol. 119: 272-279.
21. Lundy, S. K., S. Sarkar, L. A. Tesmer, and D. A. Fox. 2007. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res. Ther. 9: 202.
22. Nguyen, L. T., J. Jacobs, D. Mathis, and C. Benoist. 2007. Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum. 56: 509-520.
23. Camps, M., T. Rückle, H. Ji, V. Ardissone, F. Rintelen, J. Shaw, C. Ferrandi, C. Chabert, C. Gillieron, B. Françon, et al. 2005. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11: 936-943. (Pubitemid 41294438)
24. Bendele, A., T. McAbee, G. Sennello, J. Frazier, E. Chlipala, and D. McCabe. 1999. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum. 42: 498-506. (Pubitemid 29136098)
25. Harrington, L. E., R. D. Hatton, P. R. Mangan, H. Turner, T. L. Murphy, K. M. Murphy, and C. T. Weaver. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6: 1123-1132. (Pubitemid 41541790)
26. Zhang, L., andY. Zhao. 2007. The regulation of Foxp3 expression in regulatoryCD4 (+)CD25(+)T cells: multiple pathways on the road. J. Cell. Physiol. 211: 590-597. (Pubitemid 46683027)
27. Thorbecke, G. J., A. R. Amin, and V. K. Tsiagbe. 1994. Biology of germinal centers in lymphoid tissue. FASEB J. 8: 832-840. (Pubitemid 24268874)
28. Lorenzo, J., M. Horowitz, and Y. Choi. 2008. Osteoimmunology: interactions of the bone and immune system. Endocr. Rev. 29: 403-440. (Pubitemid 351831507)
29. Lee, S. H., T. S. Kim, Y. Choi, and J. Lorenzo. 2008. Osteoimmunology: cytokines and the skeletal system. BMB Rep 41: 495-510.
30. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136: 2348-2357. (Pubitemid 16136806)
31. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141. (Pubitemid 41541791)
32. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562. (Pubitemid 38680433)
33. Sakaguchi, S., K. Wing, Y. Onishi, P. Prieto-Martin, and T. Yamaguchi. 2009. Regulatory T cells: how do they suppress immune responses? Int. Immunol. 21: 1105-1111.
34. Gaffen, S. L. 2009. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr. Rheumatol. Rep. 11: 365-370.
35. Peck, A., and E. D. Mellins. 2009. Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin. Immunol. 132: 295-304.
36. Nickoloff, B. J., J. Z. Qin, and F. O. Nestle. 2007. Immunopathogenesis of psoriasis. Clin. Rev. Allergy Immunol. 33: 45-56. (Pubitemid 351514147)
37. McFarland, H. F., and R. Martin. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8: 913-919. (Pubitemid 47300005)
38. Liu, Z. J., P. K. Yadav, J. L. Su, J. S. Wang, and K. Fei. 2009. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 15: 5784-5788.
39. Wang, Y. H., and Y. J. Liu. 2008. The IL-17 cytokine family and their role in allergic inflammation. Curr. Opin. Immunol. 20: 697-702.
40. Kremer, J. M., B. J. Bloom, F. C. Breedveld, J. H. Coombs, M. P. Fletcher, D. Gruben, S. Krishnaswami, R. Burgos-Vargas, B. Wilkinson, C. A. Zerbini, and S. H. Zwillich. 2009. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60: 1895-1905.
41. Coombs, J. H., B. J. Bloom, F. C. Breedveld, M. P. Fletcher, D. Gruben, J. M. Kremer, R. Burgos-Vargas, B.Wilkinson, C. A. Zerbini, and S. H. Zwillich. 2010. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 69: 413-416.
42. Genovese, M. C., F. Van den Bosch, S. A. Roberson, S. Bojin, I. M. Biagini, P. Ryan, and J. Sloan-Lancaster. 2010. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62: 929-939.
43. Kremer, J. M., S. Cohen, B. E.Wilkinson, C. A. Connell, J. L. French, J. Gomez-Reino, D. Gruben, K. S. Kanik, S. Krishnaswami, V. Pascual-Ramos, et al. 2012. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP- 690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64: 970-981.
44. Leonardi, C., R. Matheson, C. Zachariae, G. Cameron, L. Li, E. Edson-Heredia, D. Braun, and S. Banerjee. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199.
45. Maeshima, K., K. Yamaoka, S. Kubo, K. Nakano, S. Iwata, K. Saito, M. Ohishi, H. Miyahara, S. Tanaka, K. Ishii, H. Yoshimatsu, and Y. Tanaka. 2011. A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-gamma and IL-17 production by human CD4(+) T cells. Arthritis Rheum. In press.
46. Smith, S. M., and C. E. Hayes. 1987. Contrasting impairments in IgM and IgG responses of vitamin A-deficient mice. Proc. Natl. Acad. Sci. USA 84: 5878-5882.
47. Morikawa, K., and M. Nonaka. 2005. All-trans-retinoic acid accelerates the differentiation of human B lymphocytes maturing into plasma cells. Int. Immunopharmacol. 5: 1830-1838. (Pubitemid 41586223)
48. Oreffo, R. O., A. Teti, J. T. Triffitt, M. J. Francis, A. Carano, and A. Z. Zallone. 1988. Effect of vitamin A on bone resorption: evidence for direct stimulation of isolated chicken osteoclasts by retinol and retinoic acid. J. Bone Miner. Res. 3: 203-210.
49. Scheven, B. A., and N. J. Hamilton. 1990. Retinoic acid and 1,25-dihydroxyvitamin D3 stimulate osteoclast formation by different mechanisms. Bone 11: 53-59. (Pubitemid 20166688)
50. Wang, X., J. Wu, Y. Shidoji, Y. Muto, N. Ohishi, K. Yagi, S. Ikegami, T. Shinki, N. Udagawa, T. Suda, and Y. Ishimi. 2002. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation. J. Bone Miner. Res. 17: 91-100. (Pubitemid 33151000)
51. Kneissel, M., A. Studer, R. Cortesi, and M. Susa. 2005. Retinoid-induced bone thinning is caused by subperiosteal osteoclast activity in adult rodents. Bone 36: 202-214. (Pubitemid 40283577)
52. Conaway, H. H., E. Persson, M. Halén, S. Granholm, O. Svensson, U. Pettersson, A. Lie, and U. H. Lerner. 2009. Retinoids inhibit differentiation of hematopoietic osteoclast progenitors. FASEB J. 23: 3526-3538.
53. Hu, L., T. Lind, A. Sundqvist, A. Jacobson, and H. Melhus. 2010. Retinoic acid increases proliferation of human osteoclast progenitors and inhibits RANKLstimulated osteoclast differentiation by suppressing RANK. PLoS ONE 5: e13305.